PTC Therapeutics said on Monday, September 21, 2026 that it completed its acquisition of ST-920 (isaralgagene civaparvovec) from Sangamo Therapeutics. ST-920 is a one-time AAV gene therapy for Fabry disease that is designed to enable long-term production of the missing alpha-galactosidase A enzyme in place of chronic enzyme replacement therapy. Under terms announced in August, PTC won the asset in Sangamo's Chapter 11 auction for $111 million upfront plus up to $100 million in approval milestones; Eli Lilly separately bought Sangamo's zinc finger programs for $50 million. ST-920 holds FDA Orphan Drug, Fast Track, and RMAT designations and EMA PRIME eligibility, and PTC expects to complete a rolling Biologics License Application for accelerated approval in the fourth quarter of 2026.
Gene-editing pioneer Sangamo Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware on Tuesday June 23, 2026, after disclosing only $27.6 million in cash as of March 31 and a May 2026 Nasdaq delisting for minimum-bid-price non-compliance. Two simultaneous asset purchase agreements established the floor. Eli Lilly is the stalking-horse bidder at $50 million cash plus assumption of certain liabilities for Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas Pharma takes the Fabry disease asset isaralgagene civaparvovec (ST-920) under a separate agreement. The Lilly bid covers the assets most relevant to the peptide-adjacent neurology pipeline, with prion protein biology offering platform optionality for Lilly's broader neurodegeneration program. Both agreements remain subject to higher-or-better offers under standard Section 363 sale procedures. Sangamo simultaneously cut 51 employees, approximately 40% of its remaining workforce, with the remainder retained through the auction and sale process. The bankruptcy closes a 30-year arc that began as the zinc-finger nuclease pioneer through gene editing's commercial first wave, and underscores that gene-editing platform capital is now consolidating into large-pharma hands.